Chelation Therapy for Childhood Lead Poisoning

Centers for Disease Control. Preventing Lead Poisoning in Young Children. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control; October 1991.

Markowitz ME , Rosen JE Need for the lead mobilization test in children with lead poisoning. J Pediatr. 1991;119:305-310.

Cory-Slechta DA , Weiss B. Efficacy of the chelating agent CaEDTA in reversing lead-induced changes in behavior. Neurotoxicology. 1990;10:685-697.

Chisolm JJ , Harrison HE The treatment of acute lead encephalopathy in children. Pediatrics. 1957;19:2-20.

Ennis JM , Harrison HE Treatment of lead encephalopathy with BAL (2.3 dimercaptopropanol) . Pediatrics. 1950;5:853-868.

Cory-Slechta DA , Weiss B. , Cox C. Mobilization and redistribution of lead over the course of calcium disodium ethylenediamine tetraacetate chelation therapy . J Pharmacol Exp Ther. 1987;243:804-813.

Chisolm JJ Evaluation of the potential role of chelation therapy in treatment of low to moderate lead exposures. Environ Health Perspect. 1990;89:67-74.

Piomelli S. , Rosen JF , et al. Management of childhood lead poisoning. J Pediatr. 1984;105:523-532.

Markowitz ME , Rosen JF Assessment of lead stores in children: validation of an 8-hour CaNa2EDTA provocative test. J Pediatr. 1984;104:337-341.

Chisolm JJ Mobilization of lead by calcium disodium edetate: a reappraisal. Am J Dis Child. 1987;141:1256-1257.

Weinberger HL , Post EM , et al. An analysis of 248 initial mobilization tests performed on an ambulatory basis. Am J Dis Child. 1987;141:1266-1270.

Shannon M. , Grace A. , Graef J. Use of urinary lead concentration in interpretation of the EDTA mobilization test. Vet Hum Toxicol. 1989;32(2):140-142.

Saenger P. , Rosen JF , Markowitz M. Diagnostic significance of edetate disodium calcium testing in children with increased lead absorption. Am J Dis Child. 1982;136:312-315.

Markowitz ME , Rosen JF , Bijur PE Effects of iron deficiency on lead excretion in children with moderate lead intoxication. J Pediatr. 1990 ;116:360-364.

Telfer JG Use ofBAL in lead poisoning. JAMA. 1947;135:835-837.

Ryder HW , Cholak J. , Kehoe RA Influence of dithiopropanol (BAL) on human lead metabolism. Science. 1947;105:63-64.

Chisolm JJ The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediatr. 1968;73:1-38.

Peters RA , Spray GH , Stocken LA , et al. The use of British anti-lewisite containing radioactive sulphur for metabolism investigations. Biochem J. 1947;41:370-373.

Spray GH , Stocken LA , Thompson Rhs. Further investigations on the metabolism of 2:3-dimercaptopropanol . Biochem J. 1947;41:362-366.

Aronson AL , Hammond PB Effect of two chelation agents on the distribution and excretion of lead. J Pharmacol Exp Ther. 1964;146:241-251.

Thomas DJ , Chisolm JJ Lead, zinc and copper decorporation during calcium disodium ethylenediamine tetraacetate treatment of lead-poisoned children. j Pharmacol Exp Ther. 1986;239:829-835.

Perry HM , Perry EF Normal concentrations of some trace metals in human urine: changes produced by ethylenediaminetetraacetate. J Clin Invest. 1959;38:1452-1463.

Foreman H. , Trujillo TT The metabolism of C14-labeled ethylenediaminetetra-acetic acid in human beings . J Lab Clin Med. 1954;43:566-571.

Jugo S. , Maljkovic T. , Kostial K. Influence of chelating agents on the gastrointestinal absorption oflead . Toxicol Appl Pharmacol. 1975;34:259-263.

Hammond PB , Aronson AL , Olson WC The mechanism of mobilization of lead by ethylenediaminetetraacetate . J Pharmacol Exp Ther. 1967;157:196-206.

Hammond PB The effects of chelating agents on the tissue distribution and excretion of lead. Toxicol Appl Pharmacol. 1971;18:296-310.

Foreman H. , Finnegan C. , Lushbaugh CC Nephrotoxic hazard from uncontrolled edathamil calcium-disodium therapy . JAMA. 1956;160:1042-1046.

Foreman H. Toxic side effects of ethylenediaminetetraacetic acid. J Chron Dis. 1963;16:319-323.

Vitale LF , Rosalinas-Bailon A. , Folland D. , et al. Oral penicillamine therapy for chronic lead poisoning in children . J Pediatr. 1973;83:1041-1045.

Chisolm JJ Chelation therapy in children with subclinical plumbism. Pediatrics. 1974;53:441-443.

Shannon M. , Graef J. , Lovejoy FH Efficacy and toxicity of D-penicillamine in low-level lead poisoning . J Pediatr. 1988;112:799-804.

Hammond PB The effects of D-penicillamine on the tissue distribution and excretion of lead. Toxicol Appl Pharmacol. 1973;26:241-246.

Russell JC , Griffin TB , McChesney EW , et al. Metabolism of airborne particulate lead in continuously exposed rats: effect of penicillamine on mobilization. Exotoxicol Environ Safety. 1978;2:49-53.

Rosen JF , Markowitz ME D-Penicillamine: its actions on lead transport in bone organ culture . Pediatr Res. 1980;14:330-335.

Besunder JB , Reed MD , Fedak MJ , et al. D-Penicillamine pharmacokinetics and pharmacodynamics in lead intoxicated children. Pediatr Res. 1989;25(4):65A.

Osman MA , Patel RB , Schuna A. , et al. Reduction in oral penicillamine absorption by food, antacid, and ferrous sulfate. Clin Pharmacol Ther. 1983;33:465-470.

Ifan A. , Welling PG Pharmacokinetics of oral 500-mg penicillamine: effect of antacids on absorption . Biopharm Drug Dispos. 1986 ;7:401-405.

Bartsocas CS , Grunt JA , Boylen GW , et al. Oral D-penicillamine and intramuscular BAL+EDTA in the treatment of lead accumulation. Acta Paediatr Scand. 1971;60:553-558.

Sachs HK , Blanksma LA , Murray EF , et al. Ambulatory treatment of lead poisoning: report of 1,155 cases . Pediatrics. 1970;46:389-396.

Marcus SM : Experience with D-penicillamine in treating lead poisoning. Vet Hum ToxicoL 1982;24:18-20.

Friedheim E. , Graziano JH , Popovac D. , et al. Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet. 1978;2:1234-1236.

Graziano JH , Leong JK , Friedheim E. 2,3-dimercaptosuccinic acid: a new agent for the treatment of lead poisoning . J Pharmacol Exp Ther. 1978;206:696-700.

Graziano JH , Lolacono NJ , Meyer P. Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations . J Pediatr. 1988;113:751-757.

Graziano JH , Lolacono NJ , Moulton T. , et al. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication . J Pediatr. 1992;120:133-139.

Cory-Slechta DA Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy. j Pharmacol Exp Ther. 1988;246:84-91.

Friedheim E. , Corvi C. , Wakker CH Meso-dimercaptosuccinic acid: a chelating agent for the treatment of mercury and lead poisoning. J Pharm Pharmacol. 1976;28:711-714.

McNeil Consumer Products Company. Chemet: A Summary of Pharmacological and Clinical Data. Seymour, IN: Central Pharmaceuticals; 1991 :8. Monograph.

Maiorino RM , Akins JM , Blaha K. , et al. Determination and metabolism of dithiol chelating agents: X. In humans, meso-2,3-dimercaptosuccinic acid is bound to plasma proteins via mixed disulfide formation. J Pharmacol Exp Ther. 1990;254:570-577.

Maiorino RM , Bruce DC , Aposhian HV Determination and metabolism of dithiol chelating agents. Toxicol Appl Pharmacol. 1989;97:338-349.

Graziano JH , Siris ES , Lolacono N. , et al. 2,3-dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharmacol Ther. 1985;37:431-438.

Aposhian HV , Aposhian MM Meso-2, 3-dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu Rev Pharmacol ToxicoL 1990;30:279-306.

Mortensen ME , Valenzuela PM Dimercaptosuccinic acid (DMSA) chelation for childhood lead poisoning. Clin Pharmacol Ther. 1991;49:(2)162.

Kapoor SC , Wielopolski L. , Graziano JH , et al. Influence of 2,3-dimercaptosuccinic acid on gastrointestinal lead absorption and whole-body lead retention. Toxicol Appl Pharmacol. 1989;97:525-529.

Graziano JH Role of 2,3-dimercaptosuccinic acid in the treatment of heavy metal poisoning. Med Toxicol. 1986 ;1:155-162.